H.B. Fuller Company (FUL) Q1 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q1 2026 earnings summary
8 Jul, 2026Executive summary
Organic revenue declined 6.6% year-over-year, with positive pricing offset by lower volumes and significant supply chain disruptions from Middle East conflict leading to raw material shortages and inflationary pressures.
Adjusted EBITDA rose 4% year-over-year to $119 million, reaching the high end of guidance, while adjusted EPS increased 6% to $0.57.
Gross margin improved by 170–180 basis points year-over-year, driven by higher product pricing, cost management, and restructuring actions.
Net income attributable to shareholders rose to $21.0 million from $13.2 million in Q1 2025.
Project Quantum Leap restructuring savings increased to $15 million for 2026 and continues to deliver margin expansion.
Financial highlights
Net revenue was $771 million, down 2.3% year-over-year, with organic revenue declining 6.6%.
Adjusted EBITDA margin expanded 90 basis points to 15.4%; adjusted gross profit margin was 31.3%, up 170 basis points.
Adjusted net income was $32 million for the quarter; net income attributable to shareholders was $21.0 million.
Cash flow from operations improved by $49 million year-over-year.
Free cash flow was $(61.7) million, reflecting higher capital expenditures.
Outlook and guidance
Fiscal 2026 net revenue expected to rise mid-single digits, with organic revenue up low single digits versus 2025.
Adjusted EBITDA guidance raised to $645 million–$675 million; adjusted EPS expected at $4.55–$4.90.
Q2 2026 net revenue expected up low single digits; adjusted EBITDA forecasted at $175 million–$185 million.
Management expects restructuring costs to continue into fiscal 2026 and 2027, with the majority of charges recognized in 2026.
Pricing actions, including a minimum 10% global price increase effective April 1, are expected to offset raw material inflation.
Latest events from H.B. Fuller Company
- Q3 2024 saw 6% EBITDA and 7% EPS growth, led by strong Construction Adhesives results.FUL
Q3 20249 Jul 2026 - Adjusted EBITDA and EPS grew 5% year-over-year, with margin gains and raised full-year guidance.FUL
Q2 20258 Jul 2026 - Q2 2026 saw strong revenue, margin, and EPS growth, with a major medical acquisition announced.FUL
Q2 202625 Jun 2026 - All proposals passed, including director elections and auditor ratification, with no shareholder questions.FUL
AGM 202616 Apr 2026 - Proxy covers director elections, auditor ratification, pay, strong results, and ESG focus.FUL
Proxy Filing4 Mar 2026 - Votes will be cast for director elections, auditor ratification, and executive pay approval.FUL
Proxy Filing4 Mar 2026 - Adjusted EPS up 20% and EBITDA up 10% year-over-year, with 2024 guidance raised.FUL
Q2 20243 Feb 2026 - Margin and EPS growth achieved through cost actions and acquisitions despite revenue headwinds.FUL
Q4 202515 Jan 2026 - FY24 revenue up 1.6%, margin at 16.6%; 2025 outlook cautious with cost and footprint actions.FUL
Q4 202410 Jan 2026